The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

EDITORIAL

Polymer-free drug-coated stents: workhorse or “niche horse”?

EuroIntervention 2018;14:732-735. DOI: 10.4244/EIJV14I7A128

1. Hôpital de la Tour, Geneva, Switzerland; 2. Ramsay Générale de Santé, Institut Cardiovasculaire Paris Sud, Massy, France


Thirteen years ago, the ELUTES trial first suggested that paclitaxel-coated stents might reduce restenosis without requiring a polymer1. However, further evaluation of similar devices was disappointing, so that the first permanent polymer-coated drug-eluting stents (DES) became the early accepted standard2-4. Over time, however, late thrombotic complications became apparent and were largely attributed to the polymer coatings5. Prolonged or indefinite dual antiplatelet therapy (DAPT) was then considered necessary by many until improved permanent and biodegradable polymers were shown to be safer, allowing the pendulum to begin slowly to swing towards less aggressive antithrombotic regimens6. More recently, thanks to better ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article

LAMPOON’s European vacation